IgA nephropathy.

Wyatt RJ, Julian BA.N Engl J Med. 2013 Jun 20;368(25):2402-14. doi: 10.1056/NEJMra1206793.PMID: 23782179 Review. 

Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.

Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants.Kidney Int. 2017 May;91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22.PMID: 28341274 

Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy.

Canney M, Barbour SJ, Zheng Y, Coppo R, Zhang H, Liu ZH, Matsuzaki K, Suzuki Y, Katafuchi R, Reich HN, Cattran D; International IgA Nephropathy Network*; International IgA Nephropathy Network Investigators.J Am Soc Nephrol. 2021 Feb;32(2):436-447. doi: 10.1681/ASN.2020030349. Epub 2020 Dec 23.PMID: 33514642

Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.

Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, Reich HN, Feehally J, Cattran DC; International IgA Nephropathy Network.JAMA Intern Med. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.PMID: 30980653 

Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome.

Jullien P, Laurent B, Berthoux F, Masson I, Dinic M, Claisse G, Thibaudin D, Mariat C, Alamartine E, Maillard N.Nephrol Dial Transplant. 2020 Jul 1;35(7):1179-1186. doi: 10.1093/ndt/gfy341.PMID: 30445530

After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.

Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Budde K, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J; STOP-IgAN Investigators.Kidney Int. 2020 Oct;98(4):1044-1052. doi: 10.1016/j.kint.2020.04.046. Epub 2020 May 22.PMID: 32450154

Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.

Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R; VALIGA study of the ERA-EDTA Immunonephrology Working Group.J Am Soc Nephrol. 2015 Sep;26(9):2248-58. doi: 10.1681/ASN.2014070697. Epub 2015 Feb 12.PMID: 25677392 

New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.

Magistroni R, D'Agati VD, Appel GB, Kiryluk K.Kidney Int. 2015 Nov;88(5):974-89. doi: 10.1038/ki.2015.252. Epub 2015 Sep 16.PMID: 26376134 

Insights into the Role of Mucosal Immunity in IgA Nephropathy.

Zhang YM, Zhang H.Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1584-1586. doi: 10.2215/CJN.04370418. Epub 2018 Jul 31.PMID: 30065067 

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.

Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Pecoits-Filho R, Correa-Rotter R, Rossing P, Sjöström CD, Umanath K, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators.Kidney Int. 2021 Jul;100(1):215-224. doi: 10.1016/j.kint.2021.03.033. Epub 2021 Apr 18.PMID: 33878338